Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

7.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
7.5K
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

4.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
4.7K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

2.8K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.8K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

5.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.1K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

8.7K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.7K
Liver Physiology01:30

Liver Physiology

4.0K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal single-cell transcriptional dynamics of murine pancreatic islet remodeling during hyperglycaemia progression.

Molecular metabolism·2026
Same author

Unlocking Selenium Chemical Space via a Programmable Synthesis Platform Bearing Cannabinoid Receptor Recognition Motifs.

Journal of the American Chemical Society·2026
Same author

Mice lacking β-arrestin-2 in melanocortin 4 receptor-expressing neurons show marked metabolic deficits.

JCI insight·2026
Same author

Aquaporin 9 regulates acetaldehyde uptake, alcohol-induced liver injury, and drinking behavior.

Alcohol, clinical & experimental research·2026
Same author

Monlunabant in adults with obesity and metabolic syndrome: Open-label extension of a phase 2a trial.

Diabetes, obesity & metabolism·2026
Same author

A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease.

Kidney international·2026

Related Experiment Video

Updated: Feb 27, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

19.9K

Hepatic β-arrestin 2 is essential for maintaining euglycemia.

Lu Zhu1, Mario Rossi1, Yinghong Cui1

  • 1Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, USA.

The Journal of Clinical Investigation
|June 27, 2017
PubMed
Summary

Enhanced hepatic glucagon receptor (GCGR) signaling due to β-arrestin 2 deficiency impairs glucose homeostasis in type 2 diabetes. Boosting β-arrestin 2 activity may suppress hepatic glucose production (HGP) for therapeutic benefit.

More Related Videos

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.4K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.0K

Related Experiment Videos

Last Updated: Feb 27, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

19.9K
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.4K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.0K

Area of Science:

  • * Metabolic disease research
  • * Molecular endocrinology
  • * Hepatocyte signaling pathways

Background:

  • * Increased hepatic glucose production (HGP) is a hallmark of type 2 diabetes.
  • * Enhanced signaling via hepatic glucagon receptors (GCGRs) contributes to impaired glucose control.
  • * GPCR-associated proteins like β-arrestins play critical roles in regulating receptor signaling.

Purpose of the Study:

  • * To investigate the role of β-arrestin 2 in regulating hepatic GCGR signaling and glucose homeostasis.
  • * To determine the impact of selective β-arrestin 2 inactivation or overexpression in hepatocytes.
  • * To explore therapeutic strategies targeting hepatic β-arrestin 2 for metabolic disorders.

Main Methods:

  • * Generation of adult mice with hepatocyte-specific inactivation or overexpression of β-arrestin 2.
  • * Assessment of hepatic glucose production, insulin sensitivity, and β-adrenergic signaling.
  • * Metabolic phenotyping, including high-fat diet challenges.

Main Results:

  • * Hepatocyte-specific β-arrestin 2 deficiency significantly increased hepatic GCGR signaling and worsened glucose homeostasis.
  • * Neither β-arrestin 1 deficiency nor altered hepatic insulin or β-adrenergic signaling were observed.
  • * Overexpression of β-arrestin 2 in hepatocytes reduced GCGR signaling and protected against high-fat diet-induced metabolic deficits.

Conclusions:

  • * Hepatic β-arrestin 2 is a critical negative regulator of glucagon receptor signaling.
  • * Targeting hepatic β-arrestin 2 activity offers a potential therapeutic strategy for suppressing HGP in type 2 diabetes.
  • * Modulating β-arrestin 2 function represents a promising approach for metabolic disease treatment.